Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Neoplasms of the CNS

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 77 articles:
HTML format
Text format



Single Articles


    November 2017
  1. NANDHU MS, Behera P, Bhaskaran V, Longo SL, et al
    Development of a function-blocking antibody against fibulin-3 as targeted reagent for glioblastoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1628.2017.
    PubMed     Text format     Abstract available


  2. CHEN Q, Cai J, Wang Q, Wang Y, et al
    Long non-coding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-Catenin pathway by scaffolding EZH2.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0605.2017.
    PubMed     Text format     Abstract available


  3. WICK W, Kessler T
    Drug repositioning meets precision in glioblastoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.2989.2017.
    PubMed     Text format     Abstract available


    October 2017
  4. BYRON SA, Tran NL, Halperin RF, Phillips JJ, et al
    Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.
    Clin Cancer Res. 2017 Oct 26. pii: clincanres.0963.2017.
    PubMed     Text format     Abstract available


  5. ACERBI F, Broggi M, Schebesch KM, Hohne J, et al
    Fluorescein-guided surgery for resection of high-grade gliomas: A multicentric prospective phase II study (FLUOGLIO).
    Clin Cancer Res. 2017 Oct 10. pii: clincanres.1184.2017.
    PubMed     Text format     Abstract available


    September 2017
  6. AVRIL T, Etcheverry A, Pineau R, Obacz J, et al
    CD90 expression controls migration and predicts dasatinib response in glioblastoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1549.2017.
    PubMed     Text format     Abstract available


  7. LI J, Wu J, Bao X, Honea N, et al
    Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients using an IVIVE-PBPK Modeling Approach.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.0983.2017.
    PubMed     Text format     Abstract available


  8. MULLER-GREVEN GM, Carlin C, Burgett ME, Ahluwalia MS, et al
    Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0249.2017.
    PubMed     Text format     Abstract available


  9. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-beta in glioblastomas.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0077.2017.
    PubMed     Text format     Abstract available


    August 2017
  10. FELSBERG J, Hentschel B, Kaulich K, Gramatzki D, et al
    Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0890.2017.
    PubMed     Text format     Abstract available


  11. ALEXANDER BM, Ba S, Berger MS, Berry DA, et al
    Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0764.2017.
    PubMed     Text format     Abstract available


  12. OLMEZ I, Brenneman B, Xiao A, Serbulea V, et al
    Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0803.2017.
    PubMed     Text format     Abstract available


  13. WANG G, Shen J, Sun J, Jiang Z, et al
    Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/beta-catenin Signaling.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0774.2017.
    PubMed     Text format     Abstract available


    July 2017
  14. ZHANG CB, Cheng W, Ren X, Wang Z, et al
    Tumor Purity As an Underlying Key Factor in Glioma.
    Clin Cancer Res. 2017 Jul 28. pii: clincanres.2598.2016.
    PubMed     Text format     Abstract available


  15. ZHAI L, Ladomersky E, Lauing KL, Wu M, et al
    Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0120.2017.
    PubMed     Text format     Abstract available


  16. PATEL SH, Poisson LM, Brat DJ, Zhou Y, et al
    T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower Grade Gliomas: A TCGA/TCIA Project.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0560.2017.
    PubMed     Text format     Abstract available


  17. OIZEL K, Chauvin C, Oliver L, Gratas C, et al
    Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.3102.2016.
    PubMed     Text format     Abstract available


  18. FAN QW, Nicolaides TP, Weiss WA
    Inhibiting 4EBP1 in glioblastoma.
    Clin Cancer Res. 2017 Jul 10. pii: clincanres.0042.2017.
    PubMed     Text format     Abstract available


  19. CANELLA A, Welker AM, Yoo JY, Xu J, et al
    Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3151.2016.
    PubMed     Text format     Abstract available


    June 2017
  20. ELLINGSON BM, Gerstner E, Smits M, Huang RY, et al
    Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials.
    Clin Cancer Res. 2017 Jun 27. pii: clincanres.2844.2016.
    PubMed     Text format     Abstract available


  21. COOK SANGAR ML, Genovesi LA, Nakamoto MW, Davis MJ, et al
    Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.2943.2016.
    PubMed     Text format     Abstract available


    April 2017
  22. BAKAS S, Akbari H, Pisapia J, Martinez-Lage M, et al
    In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the phi index.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1871.2016.
    PubMed     Text format     Abstract available



  23. Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Clin Cancer Res. 2017;23:2127.
    PubMed     Text format    


  24. BATICH KA, Reap EA, Archer GE, Sanchez-Perez L, et al
    Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Clin Cancer Res. 2017;23:1898-1909.
    PubMed     Text format     Abstract available


    March 2017

  25. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed     Text format    


    February 2017
  26. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Text format     Abstract available


    December 2016
  27. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Text format     Abstract available


  28. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Text format     Abstract available


    November 2016
  29. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Text format     Abstract available


  30. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Text format     Abstract available


    October 2016
  31. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Text format     Abstract available


  32. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  33. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Text format     Abstract available


    September 2016
  34. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Text format     Abstract available


  35. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Text format     Abstract available


    August 2016
  36. LIN F, de Gooijer MC, Hanekamp D, Chandrasekaran G, et al
    PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1276.2016.
    PubMed     Text format     Abstract available


  37. CALINESCU AA, Yadav VN, Carballo E, Kadiyala P, et al
    Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism.
    Clin Cancer Res. 2016 Aug 19. pii: clincanres.2888.2015.
    PubMed     Text format     Abstract available


  38. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Text format     Abstract available


  39. REINARTZ R, Wang S, Kebir S, Silver DJ, et al
    FUNCTIONAL SUBCLONE PROFILING FOR PREDICTION OF TREATMENT-INDUCED INTRA-TUMOR POPULATION SHIFTS AND DISCOVERY OF RATIONAL DRUG COMBINATIONS IN HUMAN GLIOBLASTOMA.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.2089.2015.
    PubMed     Text format     Abstract available


  40. LOWENSTEIN PR, Castro MG
    Multiple expressed endogenous glioma epitopes as novel vaccines for gliomas.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1477.2016.
    PubMed     Text format     Abstract available


    July 2016
  41. BALLARD P, Yates JW, Yang Z, Kim DW, et al
    Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
    PubMed     Text format     Abstract available


    June 2016
  42. KIM JE, Patel MA, Mangraviti A, Kim ES, et al
    Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.1535.2015.
    PubMed     Text format     Abstract available


  43. KALININA J, Ahn J, Devi NS, Wang L, et al
    Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.
    Clin Cancer Res. 2016 Jun 23. pii: clincanres.2965.2015.
    PubMed     Text format     Abstract available


  44. NIESSNER H, Schmitz J, Tabatabai G, Schmid A, et al
    PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.0064.2016.
    PubMed     Text format     Abstract available


  45. GENG F, Cheng X, Wu X, Yoo JY, et al
    Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis.
    Clin Cancer Res. 2016 Jun 8. pii: clincanres.2973.2015.
    PubMed     Text format     Abstract available


    May 2016
  46. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
    Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
    Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
    PubMed     Text format     Abstract available


  47. RAMPLING R, Peoples S, Mulholland PJ, James A, et al
    A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2016 May 25. pii: clincanres.0506.2016.
    PubMed     Text format     Abstract available


  48. OLOW A, Mueller S, Yang X, Hashizume R, et al
    BRAF status in personalizing treatment approaches for pediatric gliomas.
    Clin Cancer Res. 2016 May 23. pii: clincanres.1101.2015.
    PubMed     Text format     Abstract available


  49. XU R, Shimizu F, Hovinga K, Beal K, et al
    Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
    Clin Cancer Res. 2016 May 6. pii: clincanres.0048.2016.
    PubMed     Text format     Abstract available


  50. WICK W, Gorlia T, Bady P, Platten M, et al
    Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082).
    Clin Cancer Res. 2016 May 3. pii: clincanres.3153.2015.
    PubMed     Text format     Abstract available



  51. Correction: Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
    Clin Cancer Res. 2016;22:2313.
    PubMed     Text format    


    April 2016
  52. TATEISHI K, Iafrate AJ, Ho Q, Curry WT, et al
    Myc-driven glycolysis is a therapeutic target in glioblastoma.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2274.2015.
    PubMed     Text format     Abstract available


    March 2016
  53. LUN X, Wells JC, Grinshtein N, King JC, et al
    Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of Glioblastoma.
    Clin Cancer Res. 2016 Mar 22. pii: clincanres.1798.2015.
    PubMed     Text format     Abstract available


  54. YAO Y, Ye H, Qi Z, Mo L, et al
    B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


  55. PALANICHAMY K, Thirumoorthy K, Kanji S, Gordon N, et al
    Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2308.2015.
    PubMed     Text format     Abstract available


    February 2016
  56. CURRY WT, Gorrepati R, Piesche M, Sasada T, et al
    Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Anti-tumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
    Clin Cancer Res. 2016 Feb 12. pii: clincanres.2163.2015.
    PubMed     Text format     Abstract available


    December 2015
  57. KEBIR S, Fimmers R, Galldiks N, Schaefer N, et al
    Late Pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Clin Cancer Res. 2015 Dec 16. pii: clincanres.1334.2015.
    PubMed     Text format     Abstract available


  58. MARTUSCELLO RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, et al
    A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.0916.2015.
    PubMed     Text format     Abstract available


    November 2015
  59. MA Y, Tang N, Thompson RC, Mobley B, et al
    InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma.
    Clin Cancer Res. 2015 Nov 11. pii: clincanres.1677.2015.
    PubMed     Text format     Abstract available


  60. ANDRONESI OC, Loebel F, Bogner W, Marjanska M, et al
    Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate.
    Clin Cancer Res. 2015 Nov 3. pii: clincanres.0656.2015.
    PubMed     Text format     Abstract available


    October 2015
  61. HUANG RY, Rahman R, Ballman KV, Felten S, et al
    The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.3040.2014.
    PubMed     Text format     Abstract available


  62. JACKSON CM, Kochel CM, Nirschl CJ, Durham NM, et al
    Systemic Tolerance Mediated by Melanoma Brain Tumors is Reversible by Radiotherapy and Vaccination.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1516.2015.
    PubMed     Text format     Abstract available


  63. VERREAULT M, Schmitt C, Goldwirt L, Pelton K, et al
    Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas.
    Clin Cancer Res. 2015 Oct 19. pii: clincanres.1015.2015.
    PubMed     Text format     Abstract available


  64. MAR N, Desjardins A, Vredenburgh JJ
    CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma-The Progress and the Limitations.
    Clin Cancer Res. 2015;21:4248-50.
    PubMed     Text format     Abstract available


    September 2015
  65. PHAM CD, Flores C, Yang C, Pinheiro EM, et al
    Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma.
    Clin Cancer Res. 2015 Sep 24. pii: clincanres.0713.2015.
    PubMed     Text format     Abstract available



  66. Correction: PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas.
    Clin Cancer Res. 2015;21:4243.
    PubMed     Text format    


    July 2015
  67. SINGH SK, Venugopal C, Hallett R, Vora P, et al
    Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells.
    Clin Cancer Res. 2015 Jul 7. pii: clincanres.3147.2014.
    PubMed     Text format     Abstract available


    June 2015
  68. KIM SJ, Lee HJ, Kim SW, Choi HJ, et al
    Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice.
    Clin Cancer Res. 2015 Jun 23. pii: clincanres.3195.2014.
    PubMed     Text format     Abstract available


  69. HANNIFORD D, Zhong J, Koetz L, Gaziel-Sovran A, et al
    A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis.
    Clin Cancer Res. 2015 Jun 18. pii: clincanres.2566.2014.
    PubMed     Text format     Abstract available


  70. BROWN CE, Badie B, Barish ME, Weng L, et al
    Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T cells in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2015 Jun 9. pii: clincanres.0428.2015.
    PubMed     Text format     Abstract available


    May 2015
  71. SHI Y, Chen C, Yu S, Liu Q, et al
    miR-663 suppresses oncogenic function of CXCR4 in glioblastoma.
    Clin Cancer Res. 2015 May 28. pii: clincanres.2807.2014.
    PubMed     Text format     Abstract available


    March 2015
  72. KLUGER H, Zito CR, Barr M, Baine M, et al
    Characterization of PD-L1 Expression and Associated T cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
    Clin Cancer Res. 2015 Mar 18. pii: clincanres.3073.2014.
    PubMed     Text format     Abstract available


    February 2015
  73. CARVAJAL RD, Lawrence DP, Weber J, Gajewski TF, et al
    Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
    Clin Cancer Res. 2015 Feb 18. pii: clincanres.1630.2014.
    PubMed     Text format     Abstract available


    January 2015
  74. HOFER S, Mengele K, Schmitt M, Pestalozzi B, et al
    Complement activation and rituximab distribution in CNS NHL--letter.
    Clin Cancer Res. 2015;21:490.
    PubMed     Text format    


  75. MORENO L, Marshall LV, Pearson AD, Morland B, et al
    A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
    Clin Cancer Res. 2015;21:267-73.
    PubMed     Text format     Abstract available


  76. MERINO DM, Shlien A, Villani A, Pienkowska M, et al
    Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups.
    Clin Cancer Res. 2015;21:184-92.
    PubMed     Text format     Abstract available


    May 2014
  77. CHEN G, Chakravarti N, Aardalen K, Lazar AJ, et al
    Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
    Clin Cancer Res. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: